227 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (102)
- Blood Disorders (1)
- Cancer (7)
- Diabetes (4)
- Endocrine & Metabolic Disease (3)
- Eye (1)
- Gastrointestinal and Digestive Diseases (1)
- Healthy Volunteers (3)
- Heart Disease (11)
- Infectious Disease (3)
- (-) Kidney Disease (1)
- Liver Disease (52)
- Lung Disease (1)
- Nutrition (1)
- Obesity (3)
- Obstetrics & Gynecology (1)
- Pediatrics (1)
- Transplant (8)
Displaying 1 - 4 of 4
Condition: Kidney Disease
Investigator: Jai Radhakrishnan, MD
Status: Closed
This study is for patients with autosomal dominant polycystic kidney disease (ADPKD). The purpose of this study is to test the effectiveness of a study drug called tolvaptan. Tolvaptan continues to be studied in this trial as a possible treatment for ADPKD. ADPKD is a disease that causes kidney…
Condition: Liver Disease / NASH
Investigator: Elizabeth Verna, MD
Status: Closed
This is a 5-year, longitudinal, observational study of patients with NAFL or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. The main purpose of this research study is to collect and study information on patients with NAFLD/NASH.The goal of this study is to observe any treatment…
Condition: Liver Disease / NASH
Investigator: Elizabeth Verna, MD
Status: Closed
Patients who have been diagnosed with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis may be eligible to participate in this clinical trial. NASH is liver inflammation and damage caused by a buildup of fat in the liver. The main purpose of the study is to test the safety and…
Condition: Liver Disease / NASH
Investigator: Julia Wattacheril, MD, MPH
Status: Closed
The Sponsor is conducting this study to find out how safe and effective the investigational drug (alsocalled a study drug) obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by NASH. Currently, there are no therapies approved for the treatment of NASH. OCA (the brand name is Ocaliva) has been approved in several…